Navigation Links
GSA Selects Cascades Technologies, Inc. (CTi) to Support USA.gov
Date:1/3/2008

budget. As an 8(a) certified, Hispanic-owned business, CTi's primary customers are civilian agencies within the Federal government and commercial clients. They are listed on the GSA IT-70 Schedule. In addition to the Herndon headquarters, CTi has established offices in Washington, DC, Sterling, Va. and San Juan, Puerto Rico.

To learn more about Cascades Technologies, Inc. (CTi), call 703.793.7222 or visit http://www.cascadestech.com


'/>"/>
SOURCE Cascades Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
2. GeneSeek Selects the British Midlands as Base for New UK/European Operations
3. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
4. E-Rad Solutions Selects Compressus Enterprise Systems Integration Technology to Fuel Entry Into Teleradiology Market
5. Detroit Department of Health and Wellness Promotion Selects Netsmart Technologies Public Health Software
6. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
7. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
8. Healthcare Technologies, Ltd. Receives Notice From Nasdaq
9. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
10. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
11. ReBuilder Medical Technologies, Inc.s Recent Stock Price Volatility Explained
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5
Breaking Biology News(10 mins):Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4Jatropha Couple Oil Crop Cultivation Technology Commercially Released 13320 1Jatropha Couple Oil Crop Cultivation Technology Commercially Released 13320 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 13320 3Innovator 26apos 3Bs Studio offers Social Media Strategy Intensive Sept 16 17 2009 53443 1Innovator 26apos 3Bs Studio offers Social Media Strategy Intensive Sept 16 17 2009 53443 2Innovator 26apos 3Bs Studio offers Social Media Strategy Intensive Sept 16 17 2009 53443 3Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on 4809 1Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on 4809 2Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on 4809 3Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on 4809 4Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on 4809 5